Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan. Fulcrum granted stock options to purchase an aggregate of 478,820 shares of the Company’s common stock to four new employees, including a grant of 400,000 shares to Santiago Arroyo, M.D., Ph.D., the Company’s newly appointed Chief Medical Officer. The award was granted as of November 7, 2022, pursuant to the Company’s 2022 Inducement Stock Incentive Plan, as an inducement material to new employees entering into employment with Fulcrum Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $5.61 per share, the closing price per share of the Company’s common stock
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumGlobeNewswire
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerGlobeNewswire
- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $14.00 price target on the stock.MarketBeat
FULC
Earnings
- 2/27/24 - Beat
FULC
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- FULC's page on the SEC website